- Home
- XNCR vs JANX Comparison
XNCR vs JANX Comparison
Compare XNCR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | JANX |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.9M | 847.1M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XNCR | JANX |
|---|---|---|
| Price | $11.93 | $14.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | $22.33 | ★ $47.00 |
| AVG Volume (30 Days) | 648.0K | ★ 877.9K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,576,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 13.65 | N/A |
| 52 Week Low | $6.92 | $12.12 |
| 52 Week High | $18.69 | $35.34 |
Technical Indicators
Market Signals| Indicator | XNCR | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 49.30 |
| Support Level | $10.83 | $13.15 |
| Resistance Level | $12.87 | $14.57 |
| Average True Range (ATR) | 0.58 | 0.52 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 46.07 | 67.81 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.